Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

2.

Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.

Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, Frean J, Wiesner L, Barnes KI.

Malar J. 2019 Jun 24;18(1):209. doi: 10.1186/s12936-019-2841-8.

3.

Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.

Chotsiri P, Denoeud-Ndam L, Baudin E, Guindo O, Diawara H, Attaher O, Smit M, Guerin PJ, Doumbo OK, Wiesner L, Barnes KI, Hoglund RM, Dicko A, Etard JF, Tarning J.

Clin Pharmacol Ther. 2019 Jun 1. doi: 10.1002/cpt.1531. [Epub ahead of print]

PMID:
31152555
4.

Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.

Banda CG, Barnes KI, Maartens G.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00576-19. doi: 10.1128/AAC.00576-19. Print 2019 Jun. No abstract available.

PMID:
31126920
5.

Complex interactions between malaria and malnutrition: a systematic literature review.

Das D, Grais RF, Okiro EA, Stepniewska K, Mansoor R, van der Kam S, Terlouw DJ, Tarning J, Barnes KI, Guerin PJ.

BMC Med. 2018 Oct 29;16(1):186. doi: 10.1186/s12916-018-1177-5.

6.

Strength in Numbers: The WWARN Case Study of Purpose-Driven Data Sharing.

Humphreys GS, Tinto H, Barnes KI.

Am J Trop Med Hyg. 2019 Jan;100(1):13-15. doi: 10.4269/ajtmh.18-0649.

7.

Secondary analysis and participation of those at the data source.

Merson L, Guérin PJ, Barnes KI, Ntoumi F, Gaye O.

Lancet Glob Health. 2018 Sep;6(9):e965. doi: 10.1016/S2214-109X(18)30341-3. No abstract available.

8.

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.

Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P; WWARN Amodiaquine PK Study Group.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e02193-17. doi: 10.1128/AAC.02193-17. Print 2018 Oct.

9.

Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.

Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J.

PLoS Med. 2018 Jun 12;15(6):e1002579. doi: 10.1371/journal.pmed.1002579. eCollection 2018 Jun.

10.

Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria.

de Kock M, Tarning J, Workman L, Allen EN, Tekete MM, Djimde AA, Bell DJ, Ward SA, Barnes KI, Denti P.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01370-17. doi: 10.1128/AAC.01370-17. Print 2018 May.

11.

Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa.

Taylor WR, Naw HK, Maitland K, Williams TN, Kapulu M, D'Alessandro U, Berkley JA, Bejon P, Okebe J, Achan J, Amambua AN, Affara M, Nwakanma D, van Geertruyden JP, Mavoko M, Lutumba P, Matangila J, Brasseur P, Piola P, Randremanana R, Lasry E, Fanello C, Onyamboko M, Schramm B, Yah Z, Jones J, Fairhurst RM, Diakite M, Malenga G, Molyneux M, Rwagacondo C, Obonyo C, Gadisa E, Aseffa A, Loolpapit M, Henry MC, Dorsey G, John C, Sirima SB, Barnes KI, Kremsner P, Day NP, White NJ, Mukaka M.

BMC Med. 2018 Jan 18;16(1):11. doi: 10.1186/s12916-017-0990-6.

12.

Response to "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy".

de Kock M, Tarning J, Barnes KI, Denti P.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):731. doi: 10.1002/psp4.12256. Epub 2017 Oct 20. No abstract available.

13.

Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.

de Kock M, Tarning J, Workman L, Nyunt MM, Adam I, Barnes KI, Denti P.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):430-438. doi: 10.1002/psp4.12181. Epub 2017 Jun 9.

14.

Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa.

Gutierrez MM, Pillai G, Felix S, Romero F, Onyango KO, Owusu-Agyei S, Asante KP, Barnes KI, Sinxadi P, Allen E, Abdulla S, Masimirembwa C, Munyoro M, Yimer G, Gebre-Mariam T, Spector J, Ogutu B.

Clin Pharmacol Ther. 2017 Nov;102(5):786-795. doi: 10.1002/cpt.695. Epub 2017 Jun 5. Review.

PMID:
28378903
15.

Working towards consensus on methods used to elicit participant-reported safety data in uncomplicated malaria clinical drug studies: a Delphi technique study.

Mandimika N, Barnes KI, Chandler CI, Pace C, Allen EN.

Malar J. 2017 Jan 28;16(1):52. doi: 10.1186/s12936-017-1699-x.

16.

Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.

Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, Ouedraogo JB, Borrmann S, Mwai L, Nsanzabana C, Price RN, Dahal P, Sambol NC, Parikh S, Nosten F, Ashley EA, Phyo AP, Lwin KM, McGready R, Day NP, Guerin PJ, White NJ, Barnes KI, Tarning J.

PLoS Med. 2017 Jan 10;14(1):e1002212. doi: 10.1371/journal.pmed.1002212. eCollection 2017 Jan.

17.

Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger.

Denoeud-Ndam L, Dicko A, Baudin E, Guindo O, Grandesso F, Diawara H, Sissoko S, Sanogo K, Traoré S, Keita S, Barry A, de Smet M, Lasry E, Smit M, Wiesner L, Barnes KI, Djimde AA, Guerin PJ, Grais RF, Doumbo OK, Etard JF.

BMC Med. 2016 Oct 24;14(1):167.

18.

Correction: Hitting a Moving Target: A Model for Malaria Elimination in the Presence of Population Movement.

Silal SP, Little F, Barnes KI, White LJ.

PLoS One. 2016 Jul 14;11(7):e0159784. doi: 10.1371/journal.pone.0159784. eCollection 2016.

19.

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.

Kredo T, Mauff K, Workman L, Van der Walt JS, Wiesner L, Smith PJ, Maartens G, Cohen K, Barnes KI.

BMC Infect Dis. 2016 Jan 27;16:30. doi: 10.1186/s12879-016-1345-1.

20.

Hitting a Moving Target: A Model for Malaria Elimination in the Presence of Population Movement.

Silal SP, Little F, Barnes KI, White LJ.

PLoS One. 2015 Dec 21;10(12):e0144990. doi: 10.1371/journal.pone.0144990. eCollection 2015. Erratum in: PLoS One. 2016;11(7):e0159784.

21.

Predicting the impact of border control on malaria transmission: a simulated focal screen and treat campaign.

Silal SP, Little F, Barnes KI, White LJ.

Malar J. 2015 Jul 12;14:268. doi: 10.1186/s12936-015-0776-2.

22.

A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study.

Denoeud-Ndam L, Dicko A, Baudin E, Guindo O, Grandesso F, Sagara I, Lasry E, Palma PP, Parra AM, Stepniewska K, Djimde AA, Barnes KI, Doumbo OK, Etard JF.

BMC Infect Dis. 2015 Jun 12;15:228. doi: 10.1186/s12879-015-0963-3.

23.

The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.

WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group, Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, Barnes KI, Bassat Q, Baudin E, Björkman A, Bompart F, Bonnet M, Borrmann S, Brasseur P, Bukirwa H, Checchi F, Cot M, Dahal P, D'Alessandro U, Deloron P, Desai M, Diap G, Djimde AA, Dorsey G, Doumbo OK, Espié E, Etard JF, Fanello CI, Faucher JF, Faye B, Flegg JA, Gaye O, Gething PW, González R, Grandesso F, Guerin PJ, Guthmann JP, Hamour S, Hasugian AR, Hay SI, Humphreys GS, Jullien V, Juma E, Kamya MR, Karema C, Kiechel JR, Kremsner PG, Krishna S, Lameyre V, Ibrahim LM, Lee SJ, Lell B, Mårtensson A, Massougbodji A, Menan H, Ménard D, Menéndez C, Meremikwu M, Moreira C, Nabasumba C, Nambozi M, Ndiaye JL, Nikiema F, Nsanzabana C, Ntoumi F, Ogutu BR, Olliaro P, Osorio L, Ouédraogo JB, Penali LK, Pene M, Pinoges L, Piola P, Price RN, Roper C, Rosenthal PJ, Rwagacondo CE, Same-Ekobo A, Schramm B, Seck A, Sharma B, Sibley CH, Sinou V, Sirima SB, Smith JJ, Smithuis F, Somé FA, Sow D, Staedke SG, Stepniewska K, Swarthout TD, Sylla K, Talisuna AO, Tarning J, Taylor WR, Temu EA, Thwing JI, Tjitra E, Tine RC, Tinto H, Vaillant MT, Valecha N, Van den Broek I, White NJ, Yeka A, Zongo I.

BMC Med. 2015 Mar 31;13:66. doi: 10.1186/s12916-015-0301-z.

24.

Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria.

White NJ, Ashley EA, Recht J, Delves MJ, Ruecker A, Smithuis FM, Eziefula AC, Bousema T, Drakeley C, Chotivanich K, Imwong M, Pukrittayakamee S, Prachumsri J, Chu C, Andolina C, Bancone G, Hien TT, Mayxay M, Taylor WR, von Seidlein L, Price RN, Barnes KI, Djimdé A, ter Kuile F, Gosling R, Chen I, Dhorda MJ, Stepniewska K, Guérin P, Woodrow CJ, Dondorp AM, Day NP, Nosten FH.

Malar J. 2014 Dec 9;13:483. doi: 10.1186/1475-2875-13-483. Review.

25.

Towards malaria elimination in Mpumalanga, South Africa: a population-level mathematical modelling approach.

Silal SP, Little F, Barnes KI, White LJ.

Malar J. 2014 Aug 3;13:297. doi: 10.1186/1475-2875-13-297.

26.

Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN).

Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ, Tarning J.

Antimicrob Agents Chemother. 2014 Jul;58(7):3889-94. doi: 10.1128/AAC.02362-14. Epub 2014 Apr 28.

27.

How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials.

Allen EN, Mushi AK, Massawe IS, Vestergaard LS, Lemnge M, Staedke SG, Mehta U, Barnes KI, Chandler CI.

BMC Med Res Methodol. 2013 Nov 14;13:140. doi: 10.1186/1471-2288-13-140.

28.

Exploring the seasonality of reported treated malaria cases in Mpumalanga, South Africa.

Silal SP, Barnes KI, Kok G, Mabuza A, Little F.

PLoS One. 2013 Oct 29;8(10):e76640. doi: 10.1371/journal.pone.0076640. eCollection 2013.

29.

Re-defining the extent of malaria transmission in South Africa: implications for chemoprophylaxis.

Morris N, Frean J, Baker L, Ukpe IS, Barnes KI, Kruger P, Mabuza A, Raswiswi E, Maharaj R, Blumberg L, Moonasar D.

S Afr Med J. 2013 Oct 2;103(11):861-4. doi: 10.7196/samj.7533.

PMID:
24148174
30.

Case management of malaria: treatment and chemoprophylaxis.

Upke IS, Moonasar D, Raman J, Barnes KI, Baker L, Blumberg L.

S Afr Med J. 2013 Aug 29;103(10 Pt 2):793-8. doi: 10.7196/samj.7443.

PMID:
24079636
31.
32.

Clinical pharmacology becomes a specialty in South Africa.

Walubo A, Barnes KI, Kwizera E, Greeff O, Rosenkranz B, Maartens G.

S Afr Med J. 2013 Jan 9;103(3):150-1. doi: 10.7196/samj.6639.

PMID:
23472687
33.

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.

Svensson E, van der Walt JS, Barnes KI, Cohen K, Kredo T, Huitema A, Nachega JB, Karlsson MO, Denti P.

Br J Clin Pharmacol. 2012 Sep;74(3):465-76. doi: 10.1111/j.1365-2125.2012.04205.x.

34.

Preventing disease and saving lives: the malaria season is upon us.

Moonasar D, Asomugha C, Baker L, Blumberg L, Barnes KI, Maharaj R, Benson F.

S Afr Med J. 2011 Nov 25;101(12):865-7. No abstract available.

PMID:
22273020
35.

Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out.

Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI.

PLoS One. 2011;6(10):e25992. doi: 10.1371/journal.pone.0025992. Epub 2011 Oct 14.

36.

Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Kredo T, Mauff K, Van der Walt JS, Wiesner L, Maartens G, Cohen K, Smith P, Barnes KI.

Antimicrob Agents Chemother. 2011 Dec;55(12):5616-23. doi: 10.1128/AAC.05265-11. Epub 2011 Sep 26.

37.

Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali.

Tekete MM, Toure S, Fredericks A, Beavogui AH, Sangare CP, Evans A, Smith P, Maiga H, Traore ZI, Doumbo OK, Barnes KI, Djimde AA.

Malar J. 2011 Sep 21;10:275. doi: 10.1186/1475-2875-10-275.

38.

Parenteral artesunate access programme aims at reducing malaria fatality rates in South Africa.

Kift EV, Kredo T, Barnes KI.

S Afr Med J. 2011 Apr;101(4):240-1. No abstract available.

PMID:
21786724
39.

Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN).

Lourens C, Watkins WM, Barnes KI, Sibley CH, Guerin PJ, White NJ, Lindegardh N.

Malar J. 2010 Dec 25;9:375. doi: 10.1186/1475-2875-9-375.

40.

Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria.

Mehta U, Allen E, Barnes KI.

Expert Rev Clin Pharmacol. 2010 Jul;3(4):509-25. doi: 10.1586/ecp.10.37.

PMID:
22111680
41.

Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique.

Raman J, Little F, Roper C, Kleinschmidt I, Cassam Y, Maharaj R, Barnes KI.

Am J Trop Med Hyg. 2010 May;82(5):788-94. doi: 10.4269/ajtmh.2010.09-0401.

42.

Nonlinear mixed effects modeling of gametocyte carriage in patients with uncomplicated malaria.

Distiller GB, Little F, Barnes KI.

Malar J. 2010 Feb 26;9:60. doi: 10.1186/1475-2875-9-60.

43.

In vivo parasitological measures of artemisinin susceptibility.

Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U, Day NP, de Vries PJ, Dorsey G, Guthmann JP, Mayxay M, Newton PN, Olliaro P, Osorio L, Price RN, Rowland M, Smithuis F, Taylor WR, Nosten F, White NJ.

J Infect Dis. 2010 Feb 15;201(4):570-9. doi: 10.1086/650301.

44.

Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia.

Barnes KI, Chanda P, Ab Barnabas G.

Malar J. 2009 Oct 12;8 Suppl 1:S8. doi: 10.1186/1475-2875-8-S1-S8. Review.

45.

Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy.

Nyunt MM, Adam I, Kayentao K, van Dijk J, Thuma P, Mauff K, Little F, Cassam Y, Guirou E, Traore B, Doumbo O, Sullivan D, Smith P, Barnes KI.

Clin Pharmacol Ther. 2010 Feb;87(2):226-34. doi: 10.1038/clpt.2009.177. Epub 2009 Sep 23.

PMID:
19776738
46.
47.

Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria.

Pearce RJ, Pota H, Evehe MS, Bâ el-H, Mombo-Ngoma G, Malisa AL, Ord R, Inojosa W, Matondo A, Diallo DA, Mbacham W, van den Broek IV, Swarthout TD, Getachew A, Dejene S, Grobusch MP, Njie F, Dunyo S, Kweku M, Owusu-Agyei S, Chandramohan D, Bonnet M, Guthmann JP, Clarke S, Barnes KI, Streat E, Katokele ST, Uusiku P, Agboghoroma CO, Elegba OY, Cissé B, A-Elbasit IE, Giha HA, Kachur SP, Lynch C, Rwakimari JB, Chanda P, Hawela M, Sharp B, Naidoo I, Roper C.

PLoS Med. 2009 Apr 14;6(4):e1000055. doi: 10.1371/journal.pmed.1000055. Epub 2009 Apr 14.

48.

Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?

Zikusooka CM, McIntyre D, Barnes KI.

Malar J. 2008 Sep 15;7:176. doi: 10.1186/1475-2875-7-176.

49.

Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.

Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, Durrheim D, Roper C, Watkins B, White NJ.

J Infect Dis. 2008 Jun 1;197(11):1605-13. doi: 10.1086/587645.

PMID:
18471066
50.

Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.

Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, Barnes KI.

Eur J Clin Pharmacol. 2008 Jul;64(7):683-90. doi: 10.1007/s00228-007-0452-8. Epub 2008 Apr 16.

Supplemental Content

Loading ...
Support Center